Hottest Stocks
(Over $10)		 Hottest Stocks
($2-$10)		 Biggest Losers
(Over $10)		 Biggest Losers
($2-$10)		 Hottest
Industries		 Hottest
Sectors		 EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Novartis AG (NVS : NYSE)
 
 • Company Description   
Novartis has one of the strongest and broadest portfolio of oncology drugs and generics. It continues to build depth in 5 core therapeutic areas Cardio-Renal, Immunology, Neuroscience, Oncology and Hematology, strength in technology platforms - Targeted Protein Degradation, Cell Therapy, Gene Therapy, Radioligand Therapy, and xRNA. Novartis efforts to strengthen its wide and deep oncology portfolio by developing breakthrough treatments. Cosentyx, Entresto, Kesimpta, Zolgensma, Kisqali and Leqvio. In March 2015, Novartis acquired certain oncology products and pipeline compounds from Glaxo. In exchange, it sold its non-influenza Vaccines business to Glaxo. Also, the company has spun off the Alcon business into a separate company. In January 2015, Novartis divested its Animal Health division to Lilly. In July 2015, the company divested its influenza vaccines business to CSL Limited. Novartis has also acquired The Medicines Company, adding Leqvio, to its portfolio. Novartis sold its investment in Roche.

Number of Employees: 101,703

 
 • Price / Volume Information   
Yesterday's Closing Price: $92.00 Daily Weekly Monthly
20 Day Moving Average: 2,698,065 shares
Shares Outstanding: 2,212.60 (millions)
Market Capitalization: $203,559.20 (millions)
Beta: 0.52
52 Week High: $94.26
52 Week Low: $74.09
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 8.08% 4.72%
12 Week 1.32% -6.11%
Year To Date 1.41% -4.32%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
LICHTSTRASSE 35
-
BASEL,V8 CH 4056
CHE		 ph: 41-61-324-1111
fax: 41-61-324-7826		 investor.relations@novartis.com http://www.novartis.com
 
 • General Corporate Information   
Officers
Vasant Narasimhan - Chief Executive Officer
Joerg Reinhardt - Chairman
Enrico Vanni - Vice Chairman
Harry Kirsch - Chief Financial Officer
Nancy C. Andrews - Director

Peer Information
Novartis AG (AGN.)
Novartis AG (ABBV)
Novartis AG (NVO)
Novartis AG (LLY)
Novartis AG (RHHBY)
Novartis AG (JNJ)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: Large Cap Pharma
Sector: Medical
CUSIP: 66987V109
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 12/01/22
Next Expected EPS Date: 04/25/23
Share - Related Items
Shares Outstanding: 2,212.60
Most Recent Split Date: 5.00 (2.00:1)
Beta: 0.52
Market Capitalization: $203,559.20 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 2.47%
Current Fiscal Quarter EPS Consensus Estimate: $1.58 Indicated Annual Dividend: $2.27
Current Fiscal Year EPS Consensus Estimate: $6.53 Payout Ratio: 0.35
Number of Estimates in the Fiscal Year Consensus: 7.00 Change In Payout Ratio: 0.00
Estmated Long-Term EPS Growth Rate: 8.52% Last Dividend Paid: 03/09/2023 - $2.27
Next EPS Report Date: 04/25/23  
 

 • Fundamental Ratios
P/E
Current FY Estimate: 14.08
Trailing 12 Months: 15.06
PEG Ratio: 1.65
Price Ratios
Price/Book: 3.43
Price/Cash Flow: 15.25
Price / Sales: 4.03
EPS Growth
vs. Year Ago Period: 7.86%
vs. Previous Quarter: -4.43%
Sales Growth
vs. Year Ago Period: -4.07%
vs. Previous Quarter: 1.17%
ROE
03/31/23 - 21.79
12/31/22 - 20.89
09/30/22 - 21.88
ROA
03/31/23 - 11.03
12/31/22 - 10.62
09/30/22 - 10.89
Current Ratio
03/31/23 - 1.29
12/31/22 - 1.31
09/30/22 - 1.38
Quick Ratio
03/31/23 - 1.04
12/31/22 - 1.07
09/30/22 - 1.13
Operating Margin
03/31/23 - 26.41
12/31/22 - 25.91
09/30/22 - 26.46
Net Margin
03/31/23 - 13.75
12/31/22 - 42.66
09/30/22 - 44.56
Pre-Tax Margin
03/31/23 - 16.15
12/31/22 - 46.16
09/30/22 - 48.27
Book Value
03/31/23 - 26.86
12/31/22 - 27.52
09/30/22 - 28.48
Inventory Turnover
03/31/23 - 2.23
12/31/22 - 2.25
09/30/22 - 2.26
Debt-to-Equity
03/31/23 - 0.34
12/31/22 - 0.32
09/30/22 - 0.35
Debt-to-Capital
03/31/23 - 25.41
12/31/22 - 24.47
09/30/22 - 26.08
 

Powered by Zacks Investment Research ©